This appointment adds significant scientific and regulatory credibility to the GX-03 pipeline. Traders should watch for upcoming clinical data readouts and potential regulatory interactions, which could be catalysts for the stock.
Price Chart
Executive Summary
Turn Therapeutics appointed former CDC Director Dr. Robert R. Redfield as Chief Scientific Officer. This is a high-profile scientific hire that adds credibility to the company's GX-03 platform across atopic dermatitis, onychomycosis, and hidradenitis suppurativa, but it is a personnel change with no new financial data or clinical results disclosed.
Key Facts
- Appointed Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer.
- Dr. Redfield will contribute to scientific and clinical strategy for GX-03 across atopic dermatitis, onychomycosis, hidradenitis suppurativa, and potential additional indications.
- Dr. Redfield's research has been cited more than 40,000 times.
- Turn Therapeutics is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.
- The company is currently evaluating GX-03 in atopic dermatitis and developing it for onychomycosis.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Clinical-stage biotech risk: GX-03 may fail in later-stage trials.
- No financial data or guidance was provided in this filing.
- The company may require additional financing to fund its development programs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-098224 |
| Document: ea030480601ex99-1.htm | 0001213900-26-098224 |
| Document: 0001213900-26-098224-index-headers.html | 0001213900-26-098224 |
| Document: 0001213900-26-098224-index.html | 0001213900-26-098224 |
| Document: 0001213900-26-098224.txt | 0001213900-26-098224 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.61 (+1.34%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.61 (−12.31%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.61 (−20.70%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.61 (−22.84%) |
Aug 18, 2026 9w ago | 8-K | $9.99 | awaiting T+60 | — | $10.61 (+6.21%) |
Jul 7, 2026 15w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.61 (+9.27%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.61 (+76.25%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.61 (+67.61%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.61 (+100.57%) |
May 19, 2026 22w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.61 (+133.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers